← boardnext 2028-11
CMPS
COMPASS Pathwaysdistress 4/10 · elevated risk$11.80-1%today-22% from 52w high
Psychiatry / CNS 3
Lead: PTSD · target 5-HT2A
Revenue
pre-revenue
Liquidity
$466M
Runway
2.9 yrs
Shares 1y
+41%
Price & events
+65.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.1%
1D
-5.1%
1W
-6.7%
1M
+29.0%
3M
+64.6%
6M
+155.4%
1Y
+62.3%
2Y
-68.0%
5Y
-72.9%
All
Overview
- Market Cap
- $1.59B
- Enterprise Value
- $1.18B
- Volume
- 155.64K
- 52 Week Range
- $3.56 – $15.07
- Total Shares
- 134.95M
- Float Shares
- 101.49M
- Short %
- 7.64%
- % Held by Insiders
- 7.83%
- % Held by Institutions
- 72.45%
- RVOL
- 0.04x
- Beta
- 2.49
Pipeline stages · 2 programs
COMP360 psilocybin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Psilocybin5-HT2A
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 4 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2028-11 Estimated 50% readout ~2029-01-15 | Phase 2/3 | COMP360 psilocybin | PTSD - Post Traumatic Stress Disorder, PTSD, PTSD Symptoms, PTSD, Post Traumatic Stress Disorder | — | not yet recruiting |
| 2026-02 | Phase 3 | Psilocybin | Treatment Resistant Depression | 572 | active not recruiting |
| 2025-09 | Phase 2 | Psilocybin | Major Depressive Disorder | 102 | active not recruiting |
| 2025-05-28 | Phase 3 | Psilocybin | Treatment Resistant Depression | 255 | active not recruiting |
Upcoming readouts & decisions · our signals
1 upcoming event has our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.
Catalyst news & presentations · 3
- second half of 2026Guided 55%readoutPhase 3COMP360 · COMP006 26-week data expected in second half of 2026SEC 8-K
- early Q3 2026Guided 70%readoutPhase 3COMP360 · 26-week data from Part B of the COMP006 trial expected in early Q3 2026.SEC 8-K
- 2026-07-30Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $24 (+107% upside) · 15 analysts
- 2026-07-08StifelBuy
- 2026-07-08HC Wainwright & Co.Buy
- 2026-07-08Evercore ISI GroupIn-Line → Outperform
- 2026-07-07Morgan StanleyOverweight
- 2026-07-07OppenheimerOutperform
- 2026-07-07BTIGBuy
Competitors — 5-HT2A
- none identified
Recent news
- 2026-07-23Could COMPASS Pathways’ (CMPS) Low-Touch Psilocybin Protocol Quietly Redefine Its Competitive Edge in PTSD? - simplywall.st
- 2026-07-21CMPS Stock Clocks Muted Gains But Analysts Back Psychedelic Drug’s Durability Ahead Of FDA Filing - Stocktwits
- 2026-07-21CMPS Stock Slumps Premarket As $150M Offering Cuts Into Psychedelic Trial Buzz - Stocktwits
- 2026-07-21BranchOut Food Announces Additional $2 Million Order - GlobeNewswire
- 2026-07-20CMPS Stock Rises 23% Pre-Market As Compass Achieves Primary Endpoint In Phase 3 Treatment-Resistant Depression Trial - Stocktwits
- 2026-07-20CMPS stock trades steadily as Compass Pathways expands psilocybin depression program - Ad-hoc-news.de
- 2026-07-18Dow, S&P 500, Nasdaq Futures Dip As AI Fears Hit Software Again: Why APLD, PANW, CMPS, INFQ, IAG Are Trending After-Hours - Stocktwits
- 2026-07-18ATAI Stock Soars On Eli Lilly’s $2.8B Buyout – Why Are CMPS Shares Rising Too? - Stocktwits
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.